Mexico Brain Cancer Therapeutics Market

Mexico Brain Cancer Therapeutics Market Executive Summary

Mexico Brain Cancer Therapeutics Market valued at $35 Mn in 2022, projected to reach $79 Mn by 2030 with a 10.85% CAGR.

The irregular growth of brain cells acts as an indicator of brain cancer, with these cells displaying characteristics that can be either cancerous (malignant) or non-cancerous (benign). Despite the precise cause of brain cancer remaining elusive, identified risk factors encompass exposure to ionizing radiation and a family history of brain tumors. Typical symptoms linked to a brain tumor include headaches, gradual sensory deterioration, problems with balance, speech difficulties, and hearing challenges. The presentation of these symptoms varies based on factors like the size, location, and growth rate of the tumor. Treatment modalities for brain cancer are contingent on the type, location, and size of the tumor, with commonly employed approaches encompassing radiosurgery, chemotherapy, radiotherapy, surgery, and the application of carmustine implants.

Brain and other nervous system cancers account for approximately 1.7% of all new cancer cases in Mexico, equating to an estimated 16,963 new cases in the same year. Brain tumors make up about 1.6% of new cancer cases in Mexico. Meningiomas emerge as the predominant type of tumors within the central nervous system in Mexico, constituting a notable percentage ranging between 26-34% of all reported tumors. These statistics underscore the significance of brain and nervous system cancers in Mexico's overall cancer landscape, shedding light on the prevalence and distribution of these conditions within the population.

Bevacizumab (Avastin) in Glioblastoma Treatment: A recent Phase II clinical trial conducted in Mexico delved into the effectiveness of Avastin when used in conjunction with standard chemotherapy for glioblastoma. The study yielded promising outcomes, revealing that the combination therapy significantly prolonged progression-free survival compared to chemotherapy administered alone.

In another Phase II trial conducted in Mexico, Carfilzomib, a targeted therapy previously approved for multiple myeloma, was explored in combination with standard treatment for recurrent glioblastoma. The trial demonstrated a manageable safety profile and encouraging anti-tumor activity, prompting the need for further assessment in larger-scale trials.

Market Dynamics

Market Growth Drivers

Rising Cancer Incidence: Brain cancer cases are becoming more common in Mexico, which is consistent with a global trend. A portion of this rising trend can be ascribed to an aging population as well as lifestyle choices like smoking and being around pollutants. Improved accessibility to healthcare facilities and early detection methods are also factors contributing to the reported increase in incidence.

Expanding Treatment Options: The evolution of novel targeted therapies and immunotherapies is transforming the landscape of brain cancer treatment. Compared to traditional radiation and chemotherapy, these developments provide more accurate and maybe safer options. New drugs are being introduced to the Mexican pharmaceutical market by pharmaceutical companies that are actively involved in research and development.

Increasing Awareness and Advocacy: Media campaigns and advocacy efforts are driving an increase in public awareness of brain cancer. This leads to early discovery and increased demand for different kinds of treatment. Advocacy groups are working hard to improve treatment accessibility and address issues that affect patients and their families.

Market Restraints

Cultural and Societal Stigmas: Cultural and socioeconomic variables can impact the behavior of individuals seeking healthcare, and the existence of stigmas associated with cancer may impede prompt diagnosis and treatment beginning. Overcoming these stigmas and promoting a proactive approach to healthcare could be quite difficult.

High Treatment Costs: The considerable expenses linked to advanced medications for brain cancer treatment could present a notable obstacle. Affordability issues for specific patient groups, along with constraints in insurance coverage, may impede the widespread acceptance of costly pharmaceutical alternatives.

Regulatory Challenges: Strict regulatory processes and the protracted approval processes for novel drugs may impede the timely release of novel brain cancer treatments into the market. Challenges in the regulatory process have the potential to delay the accessibility of advanced drugs, impacting patients' timely access to cutting-edge medications.

Healthcare Policies and Regulatory Landscape

In Mexico, the Federal Committee for Protection against Sanitary Risk (COFEPRIS), which is a division of the Ministry of Health, is largely in charge of overseeing healthcare policies and having regulatory control over therapeutic drugs. COFEPRIS works in tandem with the Ministry of Health to guarantee the effectiveness, safety, and quality of medications. While the National Cancer Institute (INCan) acts as a reference organization for cancer care, the National Institute of Public Health (INSP) adds to the scientific basis for healthcare decisions. The Mexican Social Security Institute (IMSS) has an impact on drug accessibility and usage regulations for insured people, while the General Health Council provides advice on health-related matters. In addition, risk evaluation and management are facilitated by the National Commission for Protection against Health Risks (CONARIS).

Competitive Landscape

Key Players

• Pfizer
• AstraZeneca
• Merck & Co.
• Siemens
• Carestream Health
• Eisai Co.
• Genentech
• Bristol-Myers Squibb
• Eli Lilly
• Sanofi